<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H9C03657252D1416CAC1772EE6C8FF7D2" public-private="public" key="H" bill-type="olc">
<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>118 HR 3684 IH: Douglas Mike Day Psychedelic Therapy to Save Lives Act of 2023</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2023-05-25</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code>
<congress display="yes">118th CONGRESS</congress><session display="yes">1st Session</session>
<legis-num display="yes">H. R. 3684</legis-num>
<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber>
<action display="yes">
<action-date date="20230525">May 25, 2023</action-date>
<action-desc><sponsor name-id="C001120">Mr. Crenshaw</sponsor> (for himself, <cosponsor name-id="L000603">Mr. Luttrell</cosponsor>, <cosponsor name-id="B001301">Mr. Bergman</cosponsor>, <cosponsor name-id="M000194">Ms. Mace</cosponsor>, <cosponsor name-id="G000578">Mr. Gaetz</cosponsor>, <cosponsor name-id="O000172">Ms. Ocasio-Cortez</cosponsor>, <cosponsor name-id="M001217">Mr. Moskowitz</cosponsor>, <cosponsor name-id="Z000018">Mr. Zinke</cosponsor>, <cosponsor name-id="L000597">Ms. Lee of Florida</cosponsor>, <cosponsor name-id="C001110">Mr. Correa</cosponsor>, and <cosponsor name-id="V000135">Mr. Van Orden</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HAS00">Committee on Armed Services</committee-name></action-desc>
</action>
<legis-type>A BILL</legis-type>
<official-title display="yes">To direct the Secretary of Defense to establish a grant program for using psychedelic substances to treat certain conditions, and for other purposes.</official-title>
</form>
<legis-body id="H55BFBEA797724AE0AF07B471BECBDA54" style="OLC">
<section id="HE146A15CEEA140EA843BD487C557BB32" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Douglas <quote>Mike</quote> Day Psychedelic Therapy to Save Lives Act of 2023</short-title></quote>.</text></section> <section id="HF32F92688C10415EA3F5A5495D7BB2E8"><enum>2.</enum><header>Grant program of the Department of Defense to study treatment of certain conditions using certain psychedelic substances</header> <subsection id="HB4F6BFAA2B2843FE9EC8BF73E0B518EE"><enum>(a)</enum><header>Establishment</header><text display-inline="yes-display-inline">Not later than 90 days after the date of enactment of this Act, the Secretary of Defense shall award grants to eligible entities to conduct research on the treatment of members of the Armed Forces serving on active duty with a covered condition using covered psychedelic substances. Not later than 60 days after the date of the enactment of this Act, the Secretary shall designate a lead administrator to carry out the grant program under this section.</text></subsection>
<subsection id="H99E7352AD72C4736B8E9B2FA1C41BA50"><enum>(b)</enum><header>Eligible entities</header><text>The Secretary may award a grant under this section to any of the following:</text> <paragraph id="H1BDDE45C1FD34BBAA2F89763345892BE"><enum>(1)</enum><text>A department or agency of the Federal Government or a State government.</text></paragraph>
<paragraph id="H546D8625BA9B4F7AAF5DFE51F1607EDA"><enum>(2)</enum><text>An academic institution.</text></paragraph> <paragraph id="H22E1F7EE01E6490AAD12766A9E111109"><enum>(3)</enum><text>A nonprofit entity.</text></paragraph></subsection>
<subsection id="HB3135310A8CE477594EC6330F751902A"><enum>(c)</enum><header>Use of grant funds</header><text>A recipient of a grant awarded under this section may use the grant to—</text> <paragraph id="H9C5363CC2CB94609A0FF4BCB3723104C"><enum>(1)</enum><text display-inline="yes-display-inline">conduct one or more phase two clinical trials for the treatment of covered conditions that—</text>
<subparagraph id="H55CA975D3E03484B938CA48E7A98C43B"><enum>(A)</enum><text>include members of the Armed Forces serving on active duty as participants in the clinical trial; and</text></subparagraph> <subparagraph id="H7D0215AF784C4B07BEB89A9CB4720BC3"><enum>(B)</enum><text>use individual or group therapy assisted by covered psychedelic substances; or</text></subparagraph></paragraph>
<paragraph id="HA44D1C36ED3E4778B72F8EE4F3EEF79E"><enum>(2)</enum><text display-inline="yes-display-inline">train practitioners to provide treatment to members of the Armed Forces serving on active duty for covered conditions using covered psychedelic substances.</text></paragraph></subsection> <subsection id="H3A99CFE764CC4D49BDA6BBD541CD8CE0"><enum>(d)</enum><header>Participation in clinical trials</header><text display-inline="yes-display-inline">The Secretary shall authorize any member of the Armed Forces diagnosed with a covered condition to participate in a clinical trial that is conducted using a grant awarded under this section or funds provided under subsection (e) and is authorized pursuant to section 505 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>), without regard to—</text>
<paragraph id="H9BA22B387C444C96B359FCF34270A0C6"><enum>(1)</enum><text>whether the clinical trial involves a substance included in the schedule under section 202 of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/812">21 U.S.C. 812</external-xref>); or</text></paragraph> <paragraph id="H967190594D3C4F75B7B281C326EA9AD9"><enum>(2)</enum><text>section 912a of title 10, United States Code (article 112a of the Uniform Code of Military Justice).</text></paragraph></subsection>
<subsection id="H98CEBE8E8DA84C34B05B3891EF605624"><enum>(e)</enum><header>Additional authority</header><text display-inline="yes-display-inline">In addition to awarding grants under this section, the Secretary shall provide funds for a clinical research trial using covered psychedelic substances that is authorized pursuant to section 505 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>) and includes members of the Armed Forces as participants in the trial.</text></subsection> <subsection id="H3CCEA10C82C64965A1309BCD7A85A6DB"><enum>(f)</enum><header>Report required</header><text display-inline="yes-display-inline">Not later than 180 days after the date of the enactment of this Act, and every 180 days thereafter, the Secretary shall submit to the Committees on Armed Services of the House of Representatives and the Senate a report on grants awarded under this section, including the following:</text>
<paragraph id="HC0E57AF66A854CD386B3AE37437E6DA0"><enum>(1)</enum><text>Identification of clinics designated to host activities under such a grant.</text></paragraph> <paragraph id="H4E5121B200C543EE941BCA0CECADF437"><enum>(2)</enum><text>A description of entities to whom the Secretary has awarded such a grant.</text></paragraph>
<paragraph id="HDA138AD069974F06819D08140D731FCA"><enum>(3)</enum><text>The number of members of the Armed Forces who participated in a clinical trial described in subsection (d).</text></paragraph> <paragraph id="H9DB3A2C4A38641E5A74D4D06532E2756"><enum>(4)</enum><text display-inline="yes-display-inline">Information on the findings of such clinical trials.</text></paragraph></subsection>
<subsection id="H748D765B034B47FF8EE0418AD933A5F8"><enum>(g)</enum><header>Authorization of appropriations</header><text display-inline="yes-display-inline">There is authorized to be appropriated to the Secretary to carry out this section $15,000,000 for each of fiscal years 2024 through 2028.</text></subsection> <subsection id="H21DD454F8DF94EB18B2954B5AD437D83"><enum>(h)</enum><header>Definitions</header><text>In this section:</text>
<paragraph id="H08C48774FB114032931740A97D236BA6"><enum>(1)</enum><text>The term <quote>covered condition</quote> means any of the following:</text> <subparagraph id="HE7F87F5397074A5DBB8544E6C860162A"><enum>(A)</enum><text display-inline="yes-display-inline">Post-traumatic stress.</text></subparagraph>
<subparagraph id="H04BF70E9DFDA49F68D760DD9C7C23737"><enum>(B)</enum><text display-inline="yes-display-inline">Traumatic brain injury.</text></subparagraph> <subparagraph id="H784D5AFA04D443318DFAB2BC5884D3B1"><enum>(C)</enum><text>Chronic traumatic encephalopathy</text></subparagraph></paragraph>
<paragraph id="H2DDB07C88D124CB2888D6C5613473840"><enum>(2)</enum><text>The term <term>covered psychedelic substances</term> means any of the following:</text> <subparagraph id="H6706FFB6F46A421097F30DE6852E47BC"><enum>(A)</enum><text display-inline="yes-display-inline">3,4-Methylenedioxy-methamphetamine (commonly known as <quote>MDMA</quote>).</text></subparagraph>
<subparagraph id="HDF439741B0294D47BE32E6B38932532E"><enum>(B)</enum><text>Psilocybin.</text></subparagraph> <subparagraph id="H61BC767724B54B5DB10EE65FB205BE1E"><enum>(C)</enum><text>Ibogaine.</text></subparagraph>
<subparagraph id="HF9FEE2045A7D470EAA22A677BEEC8D0B"><enum>(D)</enum><text display-inline="yes-display-inline">5-Methoxy-N,N-dimethyltryptamine (commonly known as <quote>5-MeO-DMT</quote>).</text></subparagraph></paragraph> <paragraph id="H0510BFE85AE04BE2B3B1655725573508" commented="no"><enum>(3)</enum><text display-inline="yes-display-inline">The term <term>State</term> has the meaning given such term in section 901 of title 32, United States Code.</text></paragraph></subsection></section>
</legis-body>
</bill> 


